[go: up one dir, main page]

MX349827B - Compuestos que contienen nitrogeno y su uso. - Google Patents

Compuestos que contienen nitrogeno y su uso.

Info

Publication number
MX349827B
MX349827B MX2013015079A MX2013015079A MX349827B MX 349827 B MX349827 B MX 349827B MX 2013015079 A MX2013015079 A MX 2013015079A MX 2013015079 A MX2013015079 A MX 2013015079A MX 349827 B MX349827 B MX 349827B
Authority
MX
Mexico
Prior art keywords
containing compounds
nitrogen containing
compounds
preventing
formula
Prior art date
Application number
MX2013015079A
Other languages
English (en)
Other versions
MX2013015079A (es
Inventor
Bhagwat Sachin
Jagdishwar Patil Vijaykumar
Tadiparthi Ravikumar
Birajdar Satish
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013015079A publication Critical patent/MX2013015079A/es
Publication of MX349827B publication Critical patent/MX349827B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la fórmula (I): (ver Fórmula) su preparación y su uso en la prevención o el tratamiento de infecciones bacterianas.
MX2013015079A 2011-09-13 2012-09-11 Compuestos que contienen nitrogeno y su uso. MX349827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2582MU2011 2011-09-13
PCT/IB2012/054706 WO2013038330A1 (en) 2011-09-13 2012-09-11 Nitrogen containing compounds and their use

Publications (2)

Publication Number Publication Date
MX2013015079A MX2013015079A (es) 2014-01-24
MX349827B true MX349827B (es) 2017-08-14

Family

ID=47116128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015079A MX349827B (es) 2011-09-13 2012-09-11 Compuestos que contienen nitrogeno y su uso.

Country Status (13)

Country Link
US (3) US8754102B2 (es)
EP (1) EP3052497B1 (es)
JP (2) JP6114275B2 (es)
KR (1) KR101680933B1 (es)
CN (1) CN103781787B (es)
AU (1) AU2012310136B2 (es)
BR (1) BR112014003476A2 (es)
CA (1) CA2846107C (es)
ES (1) ES2640520T3 (es)
MX (1) MX349827B (es)
RU (1) RU2569307C1 (es)
WO (1) WO2013038330A1 (es)
ZA (1) ZA201308930B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
JP6114275B2 (ja) * 2011-09-13 2017-04-12 ウォックハート リミテッド 窒素含有化合物及びその使用
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
JP2015514095A (ja) 2012-03-30 2015-05-18 キュービスト ファーマシューティカルズ， インコーポレイテッド １，３，４−オキサジアゾールおよび１，３，４−チアジアゾールβ−ラクタマーゼ阻害剤
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
ES2758507T3 (es) 2012-05-30 2020-05-05 Meiji Seika Pharma Co Ltd Nuevo inhibidor de B-lactamasa y método para producir el mismo
US20150315145A1 (en) * 2012-11-01 2015-11-05 Kaneka Corporation Process for producing optically active bicyclic urea compound
JP6253676B2 (ja) * 2013-03-08 2017-12-27 ウォックハート リミテッド （２ｓ，５ｒ）−２−カルボキシアミド−７−オキソ−６−スルホオキシ−１，６−ジアザ−ビシクロ［３．２．１］オクタンのナトリウム塩のためのプロセス
KR101780577B1 (ko) * 2013-03-08 2017-09-21 욱크하르트 리미티드 (2s, 5r)-황산 모노-｛[(4-아미노피페리딘-4-일)카보닐]-7-옥소-1,6-디아자-비사이클로[3.2.1]-옥트-6-일｝에스테르의 제조 방법
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
AR097971A1 (es) 2013-10-08 2016-04-20 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
JP6411482B2 (ja) * 2013-10-11 2018-10-24 ウォックハート リミテッド 窒素含有化合物およびその使用
CA2928358A1 (en) * 2013-10-22 2015-04-30 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
CN105980385B (zh) * 2014-02-03 2018-01-09 沃克哈特有限公司 制备(2s,5r)‑1,6‑二氮杂‑二环[3.2.1]辛烷‑2‑腈‑7‑氧代‑6‑(磺氧基)‑单钠盐的方法
KR20160115941A (ko) * 2014-02-20 2016-10-06 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조합
JP2017507162A (ja) * 2014-03-14 2017-03-16 ウォックハート リミテッド 抗菌薬を含む医薬組成物
UA121383C2 (uk) 2014-03-24 2020-05-25 Новартіс Аг Органічні сполуки, що є монобактамами, для лікування бактеріальних інфекцій
WO2015150941A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of sodium (2s, 5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
JP6678116B2 (ja) * 2014-04-18 2020-04-08 ウォックハート リミテッド 抗菌剤を含む医薬組成物
WO2015159167A1 (en) * 2014-04-18 2015-10-22 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
US10294224B2 (en) 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
CA3000087A1 (en) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
CN106749242B (zh) * 2015-11-23 2021-04-02 上海医药工业研究院 阿维巴坦中间体的制备方法
HRP20221217T1 (hr) 2016-09-16 2022-12-23 Entasis Therapeutics Limited Spojevi inhibitori beta-laktamaze
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
WO2018141991A1 (en) 2017-02-06 2018-08-09 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
WO2018193368A1 (en) * 2017-04-18 2018-10-25 Wockhardt Limited Antibacterial compositions
ES2907858T3 (es) 2017-05-08 2022-04-26 Entasis Therapeutics Inc Compuestos y métodos para el tratamiento de infecciones bacterianas
AU2018304907B2 (en) 2017-07-21 2022-11-24 Antabio Sas Chemical compounds
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109870583B (zh) * 2019-04-15 2020-03-06 德阳市人民医院 急性胰腺炎相关的代谢物及其应用
WO2021165927A1 (en) 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124014C1 (ru) * 1993-12-29 1998-12-27 Пфайзер Инк. Диазабициклические соединения и содержащая их фармацевтическая композиция
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP3260551A1 (en) * 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP6114275B2 (ja) * 2011-09-13 2017-04-12 ウォックハート リミテッド 窒素含有化合物及びその使用

Also Published As

Publication number Publication date
WO2013038330A1 (en) 2013-03-21
US20140088070A1 (en) 2014-03-27
US20150141394A1 (en) 2015-05-21
AU2012310136B2 (en) 2016-07-07
CA2846107A1 (en) 2013-03-21
US8754102B2 (en) 2014-06-17
CN103781787A (zh) 2014-05-07
EP3052497A1 (en) 2016-08-10
ES2640520T3 (es) 2017-11-03
JP2014521739A (ja) 2014-08-28
NZ618286A (en) 2015-07-31
RU2569307C1 (ru) 2015-11-20
KR101680933B1 (ko) 2016-11-29
JP6114275B2 (ja) 2017-04-12
RU2014109447A (ru) 2015-11-10
US8969334B2 (en) 2015-03-03
KR20140023401A (ko) 2014-02-26
CA2846107C (en) 2016-06-21
BR112014003476A2 (pt) 2017-03-01
CN103781787B (zh) 2015-09-23
EP3052497B1 (en) 2017-06-28
MX2013015079A (es) 2014-01-24
AU2012310136A1 (en) 2013-12-19
ZA201308930B (en) 2015-02-25
US20150018312A1 (en) 2015-01-15
US9090616B2 (en) 2015-07-28
JP2016047853A (ja) 2016-04-07

Similar Documents

Publication Publication Date Title
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
PH12012501841B1 (en) Anti-infective compounds
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MY173518A (en) Antimicrobial compounds and methods of making and using the same
MY177344A (en) Compounds and their methods of use
PH12015501609A1 (en) Phenicol antibacterials
PH12015501088A1 (en) Dimeric compounds
PH12014500904B1 (en) Antibody formulations and methods
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
SG10201900541QA (en) Derivatives of xanthone compounds
MX336294B (es) Inhibidores de iap.
MX2014006686A (es) Derivaods novedosos de pirrol.
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
MX2015005753A (es) Agentes antimicrobianos.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
IN2013MU03216A (es)
PH12015500399A1 (en) Azaindolines
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
IN2015DN02109A (es)
MX356102B (es) Compuestos y métodos para tratar leucemia.

Legal Events

Date Code Title Description
FG Grant or registration